This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one.
After PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding.
This study is not testing any new intervention, rather comparing approved drugs and approved durations of use.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ≥18 years old
* Admitted because of an acute MI (either STEMI or NSTEMI).
* Invasive management during index admission with successful PCI.
* Able to consent.
Exclusion Criteria:
* Indication for oral anticoagulation therapy.
* Intolerance, contraindication or known allergy to either aspirin, prasugrel or ticagrelor.
* Prior history of ischaemic or haemorrhagic stroke or transient ischaemic attack.
* Patients with active bleeding or known bleeding disorders.
* Patients with known moderate or severe hepatic dysfunction (Child-Pugh Class B or Class C).
* Known intracranial aneurism, arteriovenous malformation or neoplasm.
* Patients with chronic kidney disease requiring dialysis.
* Any disorder that may interfere with drug absorption.
* Pregnancy or current lactation.
* Concomitant use of potent CYP3A inhibitors or inducers.
* Planned elective surgery that cannot be deferred 12 months before randomization, requiring interruption of antiplatelet therapy.
* Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year)
* Active participation in other clinical trials.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
ischemic events
Timeframe: 12 months
Trial details
NCT IDNCT07507500
SponsorInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz